{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021198","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.723905+00:00","generated_at":"2026-06-15T03:53:40.849725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eledon reports Q1 net loss $10.8M; clinical and financing updates on tegoprubart","bullets":["Net loss of $10.8M ($0.75/share) vs $9.9M ($0.69) in Q1 2022; R&D expenses rose to $8.1M.","Cash $46.5M at March 31; second-quarter financing provided $35M upfront (up to $185M) to fund Phase 2 BESTOW.","Phase 1b kidney transplant data (3 patients): no acute rejection; mean eGFR >70 mL/min/1.73m2 at timepoints up to 31 weeks.","Phase 2a IgAN study: tegoprubart safe and well tolerated; no serious/severe AEs; 4 patients completed ≥24 weeks.","Phase 2 BESTOW trial expected to initiate mid-2023; updated Phase 1b data anticipated late 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021198","json":"https://secwatch.observer/filing/0000950170-23-021198.json","markdown":"https://secwatch.observer/filing/0000950170-23-021198.md","text":"https://secwatch.observer/filing/0000950170-23-021198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023021198/0000950170-23-021198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023021198/eldn-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:53:40.849725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"914fee6bdc8864b4e08bdfdf88637dbc604944eb","claim":"Eledon Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: net income net loss of $10.8 million, or $0.75 per share, EPS $0.75 per share.","evidence_excerpt":"The Company reported a net loss of $10.8 million, or $0.75 per share, for the three months ended March 31, 2023, compared to a net loss of $9.9 million, or $0.69 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023021198/0000950170-23-021198-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"net loss of $10.8 million, or $0.75 per share"},{"label":"EPS","value":"$0.75 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}